<DOC>
	<DOCNO>NCT00603954</DOCNO>
	<brief_summary>The present project aim compare two nonmyeloablative regimen currently use 2 major HCT center US patient HLA-matched related unrelated donor : one Seattle group consist 2 Gy TBI fludarabine ( 90 mg/m² ) versus one Stanford group combine 8 Gy TLI ATG .</brief_summary>
	<brief_title>Allogeneic HCT With HLA-matched Donors : Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings</brief_title>
	<detailed_description>I . OBJECTIVES The present project aim compare two nonmyeloablative regimen currently use 2 major HCT center US patient HLA-matched related unrelated donor : one Seattle group consist 2 Gy TBI fludarabine ( 90 mg/m² ) versus one Stanford group combine 8 Gy TLI ATG . II . DESIGN OF THE STUDY The study multicenter , randomize phase II study , compare two conditioning regimen . Sixty patient HLA-matched donor randomize TBI DLI regimen . There stratification center . There stop rule graft rejection &gt; 15 % day 180 ( group separately ) , nonrelapse mortality &gt; 35 % day 180 ( group separately ) . If stopping rule trigger 60 patient statistically significant difference see 2 arm term acute GVHD , graft rejection survival , second cohort 40 patient include . III . TREATMENT PLAN III.1 . Pre-transplant procedure Peripheral blood mononucleated cell patient well donor collect conditioning , per standard practice routine allogeneic HSC transplant . Part cryopreserved 10 % DMSO store -180°C liquid nitrogen . The part devote identification specific donor patient marker use later measurement chimerism . III.2 . Conditioning regimens The conditioning regimens use either one develop Seattle ( TBI arm ) one develop Stanford group ( TLI arm ) . These 2 regimen extensively report major medical journal . In TBI arm , condition consist fludarabine 30 mg/m2 day -4 , -3 -2 ( total dose 90 mg/m2 ) , follow singe dose 2 Gy TBI administer day 0 , low dose-rate ( ≈ 7 cGy/min ) , infusion cell . In TLI arm , condition consist 8 Gy TLI ATG . TLI administer linear accelerator dose 80 cGy daily , start 11 day transplantation , total 10 dos ( 800 cGy ) deliver . The irradiation consist supradiaphragmatic mantle field , subdiaphragmatic field include inverted Y splenic port , encompass major lymphoid organ , include thymus , spleen , lymph node , use treatment Hodgkin 's disease ( Kaplan HS , Cancer Research 26:1268-1276 , 1966 ) . The Waldeyer ring include . ATG ( Thymoglobulin® , Genzyme ) , dose 1.5 mg/kg/d , give intravenously day -11 -7 . III.3 . PBSC collection transplantation PBSC mobilization collection donor perform per standard practice routine allogeneic HSC transplant . This briefly describe . The donor give SC injection G-CSF dose 10-15 µg/kg 6 day ( day -5 0 ) . Additional dos G-CSF may give day +1 +2 first 2 leukaphereses yield sufficient number CD34+ cell . G-CSF generally administer : - In even day -5 , -4 , -3 , -2 ; - Before 7:00 day -1 0 ( day 1 2 necessary ) . Collection PBSC carry day -1 morning day 0 . Leukaphereses perform use continuous flow blood cell separator follow mononuclear cell collection protocol . The volume blood process 15-20 liter donor adult 10 liters/m2 donor child . Anticoagulation perform ACD-A solution . The PBSC first day harvest store overnight 4°C patient 's plasma . After second harvest , PBSC first second day harvest infused patient . Based previous report suggest high dose CD34 cell associate well outcomes nonmyeloablative HCT , high dos CD34+ cell ( &gt; 6.5 x 106/kg ) ideally administer . Nevertheless , limit donor procedure , two leukaphereses require . However , case require minimal number cell ( 3 x 106 CD34+ cells/kg recipient ) obtain first two collection , additional leukaphereses carry unless contra-indicated donor . Cells infused central catheter accord standard procedure . III.4 . Other treatment recipient III.4.1 . Immunosuppressive therapy The immunosuppressive regimen use one used standard practice routine NM-HCT center , i.e . association tacrolimus mycophenolate mofetil ( MMF ) . MMF administer orally even day 0 day 28 ( sibling recipient ) day 42 ( alternative donor recipient ) dose 15 mg/kg t.i.d . Tacrolimus give orally dose 0.06 mg/kg bid start day -3 . The dose adapt accord whole blood value follow standard procedure ( 15 20 ng/ml first 28 day 10-15 ng/ml thereafter ) . Full dose give day 100 ( sibling recipient ) 180 ( alternative donor recipient ) . Doses progressively taper definitely discontinue day 180 ( sibling donor ) 365 ( alternative donor recipient ) absence GVHD . Tacrolimus may stop early case disease progression graft rejection continue long case low donor T-cell chimerism GVHD . GVHD assess accord standard criterion . Therapy acute chronic GVHD use standard procedures/current protocol . III.4.2 . Growth factor Growth factor use per standard practice routine NM-HCT . No myeloid growth factor administer unless granulocyte count fall 1000/µl . Patients may treat 5 µg/kg/day G-CSF maintain granulocyte count &gt; 1,000/µl . Erythropoietin may administer require . III.4.3 . Infection prophylaxis Infection prophylaxis bacterial , fungal , viral parasitic agent carry per standard practice routine NM-HCT . III.4.4 . Donor lymphocyte infusion Donor lymphocyte infusion ( DLI ) give per standard practice routine NM-HCT . DLI may give case poor T-cell chimerism disease progression accord standard procedures/current protocol . IV . PATIENTS ' FOLLOW-UP IV.1 . Quality control cell product IV.1.1 . Peripheral blood donor day PBSC collection As per standard practice routine allogeneic PBSC transplant . IV.1.2 . Leukapheresis product As per standard practice routine allogeneic PBSC transplant include determination number TNC , CD34 , CD3 , CD4 CD8 cell transplant . IV.2 . Toxicities cell infusion Potential toxicity associate PBSC infusion carefully monitor per standard procedure . IV.3 . Chimerism The chimeric status hematopoietic cell carefully monitor post-transplant , per standard practice routine allogeneic transplant . Donor chimerism measure whole blood well bone marrow . In addition , peripheral blood cell separate RosetteSep procedure ( Stem Cell Technologies , Vancouver , Canada ) determine proportion donor recipient cell pure population T ( CD3+ ) cell . Fluorescent in-situ hibridization ( FISH ) X Y chromosome use preferentially sex-mismatched HCT , PCR technique base short tandem repeat ( STR ) marker use sex-matched HCT . Pre-transplant donor recipient peripheral WBC serve identify specific marker . We define complete chimerism presence &gt; 95 % T cell donor origin mixed chimerism presence 6-94 % T cell donor origin . Graft rejection define occurrence T cell chimerism &lt; 5 % engraftment occurrence 5 % T cell donor origin first month follow transplant . The proportion donor chimerism determine following time point : 1. peripheral blood : - Days 28 , 42 , 60 , 100 , 180 365 post-transplant : whole blood CD3+ cell ; - Analyses day 60 necessary chimerism &lt; 80 % day 28 and/or 42 ; - Analyses whole blood day 42 , 100 , 180 365 necessary bone marrow analyse feasible/successful . 2. bone marrow : • Days 42 , 100 , 180 365 post-transplant : whole bone marrow . IV.4 . Clinical data Patient carefully observe follow clinical parameter record ( see appendix B C ) . Appendices B C send 3 month patient achieve target day HSCT ( day 100 , day 180 , 1-yr , 2-yr , 3-yr , 4-yr 5-yr ) Frederic Baron fax # 32-4-366 8855 . - Incidence , time severity acute GVHD , treatment outcome ; - Incidence , time severity chronic GVHD , treatment outcome ; - Incidence , time severity cytopenia , treatment outcome ; number platelet RBC transfusion ; G-CSF usage ; - Time achieve 500 neutrophil , 1000 neutrophil , 20 000 platelet 50 000 platelet ; - Duration hospitalization , ; - Incidence bacterial infection ; - Incidence fungal infection ; - Incidence CMV infection ( quantitative PCR ) CMV disease ; - Incidence viral infection ; - Incidence infection ; - Evolution primary malignant disease : response , relapse , treatment outcome ; - Any serious complication associate transplant procedure ; - Death survival . IV.5 . Immunologic data . In patient transplanted university Liège , immune reconstitution patient monitor per standard practice ULg routine allogeneic transplant . For patient transplant outside University Liège willing participate immune recovery study , 50 mL fresh heparinized blood collect day 42 , 100 , 180 , 365 730 send room temperature Olivier Dengis , Department Clinical Hematology , CHU Sart-Tilman , B4000 Liège .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<criteria>PATIENT 1 . Diseases Hematological malignancy confirm histologically rapidly progress : AML CR ( define ≤ 5 % marrow blast absence blast peripheral blood ) ; MDS ≤ 5 % marrow blast absence blast peripheral blood ; CML CP ; MPS blast crisis extensive marrow fibrosis , ALL CR ; Multiple myeloma rapidly progress ; CLL ; NonHodgkin 's lymphoma ( aggressive NHL chemosensitive disease ) ; Hodgkin 's disease chemosensitive disease . 2 . Clinical situation Theoretical indication standard allotransplant , feasible : Age &gt; 50 yr ; Unacceptable end organ performance ; Patient 's refusal . Indication standard autotransplant : perform miniallotransplantation 26 month standard autotransplant . 3 . Other inclusion criterion Male female ; fertile patient must use reliable contraception method ; Age &lt; 75 yr ; Informed consent give patient his/her guardian minor age . DONOR Related recipient ( sibling , parent child ) unrelated ; Male female ; Any age ; 10 10 ( HLAA , B , C , DRB1 , DQB1 ) HLA allele match ; Weight &gt; 15 Kg ( leukapheresis ) ; Fulfills criterion allogeneic PBSC donation accord standard procedure ; Informed consent give donor his/her guardian minor age , per donor center standard procedure . PATIENT Any condition fulfil inclusion criterion ; HIV positive ; Nonhematological malignancy ( y ) ( except nonmelanoma skin cancer ) &lt; 3 year nonmyeloablative HCT . Life expectancy severely limited disease malignancy ; Administration cytotoxic agent ( ) `` cytoreduction '' within three week prior initiate nonmyeloablative transplant conditioning ( Exceptions hydroxyurea imatinib mesylate ) ; CNS involvement disease refractory intrathecal chemotherapy . Terminal organ failure , except renal failure ( dialysis acceptable ) Uncontrolled infection ; Karnofsky Performance Score &lt; 70 % ; Patient fertile man woman unwilling use contraceptive technique 12 month follow treatment ; Patient female pregnant breastfeeding ; Previous radiation therapy precluding use 2 Gy TBI 8 Gy TLI ; DONOR Any condition fulfil inclusion criterion ; Unable undergo leukapheresis poor vein access reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Nonmyeloablative conditioning .</keyword>
	<keyword>Hematological malignancy .</keyword>
	<keyword>GVHD .</keyword>
</DOC>